Algeta ASA
oslo : ALGETA

April 17, 2013 01:09 ET

Algeta to Participate in Upcoming Investor Conference

OSLO, NORWAY--(Marketwired - Apr 17, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and IR teams will participate in the following investor conference:

Kempen & Co. 6(th) Healthcare/Life Sciences Conference

Date: 23 April 2013


Thomas Ramdahl (Chief Technology Officer)

Renate Birkeli (IR)

Venue: Amsterdam, The Netherlands

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit

Algeta to Participate in Upcoming Investor Conference:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Algeta ASA via Thomson Reuters ONE


Contact Information

  • For further information, please contact:

    Mike Booth / Renate Birkeli
    +47 23 00 67 32
    Communications & Corporate Affairs
    Email Contact

    Media enquiries:

    Mark Swallow
    +44 207 638 9571
    Citigate Dewe Rogerson
    Email Contact

    Knut Ekern
    +47 22 04 82 00
    Gambit Hill & Knowlton
    Email Contact

    Kari Watson
    +1 781 235 3060
    MacDougall Biomedical Communications
    Email Contact

    US investor enquiries:
    Tricia Swanson
    +1 646 378 2953

    The Trout Group
    Email Contact